Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Although there was a slight increase in oral semaglutide exposure when taken in combination with omeprazole (possibly due to the increase in gastric pH), the increase observed was not statistically significant and was considered by the investigators to likely not be clinically relevant
Authors Transparency Note I think its also worth disclosing that Ive tried to do my due diligence in looking for data I might be missing
Clinical Safety Profile of AOD-9604 in Obesity Treatment
Plateaus on GLP-1 therapy are normal
Zepbound is FDA-approved for weight loss in adults with obesity or those who are overweight and have a weight-related health issue
A 2025 international study of over 37 million Type 2 diabetes patients found a slightly increased NAION risk among semaglutide users, lower than earlier studies but still present
)
